中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝癌介入治疗的现状与展望

程红岩

程红岩. 肝癌介入治疗的现状与展望[J]. 临床肝胆病杂志, 2016, 32(1): 3-8. DOI: 10.3969/j.issn.1001-5256.2016.01.001
引用本文: 程红岩. 肝癌介入治疗的现状与展望[J]. 临床肝胆病杂志, 2016, 32(1): 3-8. DOI: 10.3969/j.issn.1001-5256.2016.01.001
Cheng HongYan. Interventional treatment for hepatocellular carcinoma: a review of current status and perspectives[J]. J Clin Hepatol, 2016, 32(1): 3-8. DOI: 10.3969/j.issn.1001-5256.2016.01.001
Citation: Cheng HongYan. Interventional treatment for hepatocellular carcinoma: a review of current status and perspectives[J]. J Clin Hepatol, 2016, 32(1): 3-8. DOI: 10.3969/j.issn.1001-5256.2016.01.001

肝癌介入治疗的现状与展望

DOI: 10.3969/j.issn.1001-5256.2016.01.001
详细信息
  • 中图分类号: R735.7

Interventional treatment for hepatocellular carcinoma: a review of current status and perspectives

  • 摘要: 介入治疗已成为中期肝癌首选的治疗方法。随着技术的进步,载药微球、放射微球等已应用于临床,并取得了较好的疗效。对目前已有的介入治疗方法及存在的问题进行分析总结,认为联合治疗能使肝癌患者获益更大,规范化的介入治疗是未来的发展方向。

     

  • [1]FORNER A,LLOVET JM,BRUIX J,et al.Hepatocellular carcinoma[J].Lancet,2012,379(9822):1245-1255.
    [2]EL-SERAG HB.Hepatocellular carcinoma[J].N Engl J Med,2011,365(12):1118-1127.
    [3]BOULIN M,DELHOM E,PIERREDON-FOULONGNE MA,et al.Transarterial chemoembolization for hepatocellular carcinoma:an old method,now flavor of the day[J].Diagn Interv Imaging,2015,96(6):607-615.
    [4]WNG YX,de BAERE T,IDE JM,et al.Transcatheter embolization therapy in liver cancer:an update of clinical evidences[J].Chin J Cancer Res,2015,27(2):96-121.
    [5]ZHAO Y,CAI G,LIU L,et al.Transarterial chemoembolization in hepatocellular carcinoma with vascular invasion or extrahepatic metastasis:a systematic review[J].Asia Pac J Clin Oncol,2013,9(4):357-364.
    [6]LIN G,GU J,HAN XY,et al.Selective angiography for the diagnosis of primary liver cancer[J].Chin J Radiol,1979,13:129-132.(in Chinese)林贵,顾瑨,韩莘野,等.选择性血管造影诊断原发性肝癌[J].中华放射学杂志,1979,13:129-132.
    [7]AUBC,BOUVIER A,LEBIGOT J,et al.Radiological treatment of HCC:interventional radiolgy at the heart of management[J].Diagn Interv Imaging,2015,96(6):625-636.
    [8]LIU GH,XIA F,OUYANG Q.The effect of transcatheter arterial chemoembolization on the prevention of recurrence in hepatocellular carcinoma following hepatectomy[J].J Intervent Radiol,2015,24(2):125-129.(in Chinese)刘光华,夏芳,欧阳强.肝动脉化疗栓塞对肝细胞癌切除术后预防复发的研究[J].介入放射学杂志,2015,24(2):125-129.
    [9]BOULIN M,GUIU S,CHAUFFERT B,et al.Screening of anticancer drugs for chemoembolization of hepatocellular carcinoma[J].Anticancer Drugs,2011,22(8):741-748.
    [10]IDE JM,GUIU B.Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma:a review[J].Crit Rev Oncol Hematol,2013,88(3):530-549.
    [11]CAO G,YANG RJ,ZHU X,et al.A new thermosensitive embolic agent used for arterial embolization of primary hepatocellular carcinoma:preliminary clinical trial[J].J Intervent Radiol,2015,24(7):592-596.(in Chinese)曹广,杨仁杰,朱旭,等.新型温度敏感型栓塞剂用于原发性肝癌动脉栓塞的初步临床试验[J].介入放射学杂志,2015,24(7):592-596.
    [12]IRIE T,TAKAHASHI N.Improved accumulation of lipiodol under balloon-occluded transarterial chemoembolization(B-TACE)for hepatocellular carcinoma:measurement of blood pressure at the embolized artery before and after balloon inflation[J].IVR,2009,26:49-54.
    [13]IRIE T,KURAMOCHI M,TAKAHASHI N.Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization:measurement of balloon-occluded arterial stump pressure[J].Cardiovasc Intervent Radiol,2013,36(3):706-713.
    [14]YANG YB,CHENG HY,ZHANG L,et al.Midterm outcome of a half-blind,random,control research:a new therapy that treat hypovascular liver cancer with balloon catheter to block the main artery temporarily,and then pressurize chemoembolization[J].Chin J Radiol,2012,46(8):724-729.(in Chinese)杨永波,程红岩,张亮,等.暂时阻断肿瘤动脉血流加压灌注治疗乏血供肝癌的单盲随机对照研究中期结果[J].中华放射学杂志,2012,46(8):724-729.
    [15]LAMMER J,MALAGARI K,VOGL TJ,et al.Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma:results of the PRECISION V study[J].Cardiovasc Intervent Radiol,2010,33(1):41-52.
    [16] GOIFIERI R,GIAMPALMA E,RENZULLI M,et al.Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma[J].Br J Cancer,2014,111(2):225-264.
    [17]FACCIORUSSO A,LICINIO R,MUSCATIELLO N,et al.Treansarterial chemoembolization:evidences from the literature and applications in hepatocellular carcinoma patients[J].World J Hepatol,2015,7(16):2009-2019.
    [18]XIE ZB,WANG XB,PENG YC,et al.Systematic review comparing the safety and efficacy of conventional and drug-eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma[J].Hepatol Res,2015,45(2):190-200.
    [19]HUANG K,ZHOU Q,WANG R,et al.Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma[J].J Gastroenterol Hepatol,2014,29(5):920-925.
    [20]LIU YS,QU MC,TSAI YS,et al.Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma[J].Korean J Radiol,2015,16(1):125-132.
    [21]KLOECKNER R,WEINMANN A,PRINZ F,et al.Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma[J].BMC Cancer,2015,15:465.
    [22]RADELEFF BA,STAMPFL U,SOMMER CM,et al.Transarterial ablation of hepatollular carcinoma.Status and developments[J].Radiologe,2012,52(1):44-55.
    [23]KHAJORNJIRAPHAN N,THU NA,CHOW PKH.Yttrium-90microspheres:a review of its emerging clinical indications[J].Liver Cancer,2015,4(1):6-15.
    [24]MOSCONI C,CAPPELLI A,PETTINATO C,et al.Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma:role and prespectives[J].World J Hepatol,2015,7(5):738-752.
    [25]EDELINE J,GILABERT M,GARIN E,et al.Yttrium-90 microsphere radioembolization for hepatocellular carcinoma[J].Liver Cancer,2015,4(1):16-25.
    [26]SANGRO B,SALEM R.Transerterial chemoembolization and radioembolization[J].Semin Liver Dis,2014,34(4):435-443.
    [27]SANGRO B.Survival benefit with intraarterial techniques in hepatocellular carcinoma[J].Gastroenterol Hepatol,2014,37(Suppl2):95-101.
    [28]LENCINI R,PETRUZZI P,CROCETTI L.Chemoembolization of hepatocellular carcinoma[J].Semin Intervent Radiol,2013,30(1):3-11.
    [29]NISHIKAWA H,KITA R,KIMURA T,et al.Transcatheter arterial embolic therapies for hepatocellular carcinoma:a literature review[J].Anticancer Res,2014,34(12):6877-6886.
    [30]LUO JP,HU HT,GUO CY,et al.Hyperthermochemotherapy by using heated gemcitabine perfusion combined with transcatheter arterial chemoembolization of carboplatin for primary liver carcinomas[J].J Intervent Radiol,2013,22(6):470-473.(in Chinese)骆俊朋,胡鸿涛,郭晨阳,等.吉西他滨热化疗灌注联合卡铂化疗栓塞治疗原发性肝癌临床应用研究[J].介入放射学杂志,2013,22(6):470-473.
    [31]ROSTAMBEIGI N,DEKARSKE AS,AUSTIN EE,et al.Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma[J].J Vasc Interv Radiol,2014,25(7):1075-1084.
    [32]YAO XS,YAN D,ZENG HY,et al.Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma:a clinical analysis of 50 cases[J].J Intervent Radiol,2013,22(5):381-386.(in Chinese)姚雪松,闫东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,22(5):381-386.
    [33]WANG Y,DENG T,ZENG L,et al.The efficacy and safety radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma:a meta-analysis[J].Hepatol Res,2015.[Epub ahead of print]
    [34]HAN X,LYU WF.Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma:a meta-analysis of long-term efficacy[J].J Intervent Radiol,2013,22(5):387-391.(in Chinese)含笑,吕维富.经肝动脉化疗栓塞联合射频消融治疗原发性肝癌远期疗效的荟萃分析[J].介入放射学杂志,2013,22(5):387-391.
    [35]CHEN FW,ZHENG CS,HUANG SB,et al.TACE combined with RFA for the treatment of massive primary hepatocellular carcinomas:observation of clinical efficacy and safety[J].J Intervent Radiol,2015,24(8):684-688.(in Chinese)陈付文,郑春生,黄柿兵,等.肝动脉化疗栓塞联合射频消融治疗大肝癌的临床观察[J].介入放射学杂志,2015,24(8):684-688.
    [36]ZHANG SJ,MA YL.TACE combined with percutaneous microwave ablation in treatment of large primary hepatocellular carcinoma[J].Chin J Interv Imaging Ther,2013,10(7):397-400.(in Chinese)张世杰,马亦龙.经导管动脉化疗栓塞术联合经皮微波消融治疗大肝癌[J].中国介入影像与治疗学,2013,10(7):397-400.
    [37]SONG YY,XU H,XU W,et al.Sequential therapy of TACE followed by percutaneous microwave coagulation for early-stage primary hepatocellular carcinomas:curative effect and prognostic factors[J].J Intervent Radiol,2015,24(3):210-214.(in Chinese)宋迎迎,徐浩,许伟,等.经肝动脉化疗栓塞联合经皮微波消融序贯治疗早期肝癌的疗效及预后影响因素[J].介入放射学杂志,2015,24(3):210-214.
    [38]SONG J,WANG LZ,LI X,et al.Hepatic arterial chemoembolization combined with DSA-guided radiofrequency ablation for the treatment of hepatocellular carcinoma:evaluation of the therapeutic effect[J].J Intervent Radiol,2013,22(10):810-813.(in Chinese)宋杰,王黎洲,李兴,等.肝动脉灌注化疗栓塞联合DSA引导下射频消融术治疗肝癌100例疗效评估[J].介入放射学杂志,2013,22(10):810-813.
    [39]CHEVALLIER P,BAUDIN G,ANTY R,et al.Treatment of hepatocellulcar carcinoma by thermal ablation and hepatic transarterial chemoembolization[J].Diagn Interv Imaging,2015,96(6):637-646.
    [40]HUO YR,ESLICK GD.Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma:a systematic review and meta-analysis[J].JAMA Oncol,2015,1(6):756-765.
    [41]CHOI JH,HWANG S,LEE YJ,et al.Prognostic effect of preoperative sequential transcatether arterial chemoembolization and portal vein embolization for right hepatectomy in patients with solitary hepatocellular carcinoma[J].Korean J Hepatobiliary Pancreat Surg,2015,19(2):59-65.
    [42] FORNER A,AYUSO C,VARELA M,et al.Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma:are response evaluation criteria in solid tumors reliable?[J].Cancer,2009,115(3):616-623.
    [43]LENCIONI R,LIOVET JM.Modified RECIST(mRECIST)assessment for hepatocellular carcinoma[J].Semin Liver Dis,2010,30(1):52-60.
    [44] SHIM JH,LEE HC,KIM SO,et al.Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization?A validation study of old and new models[J].Radiology,2012,262(2):708-718.
    [45]TACHER V,LIN M,DURAN R,et al.Comparison of existing response cirteria in patients with hepatocellular carcinoma treated wtih transarterial chemoembolization using a 3D quantitative approach[J].Radiology,2016,278(1):275-284.
    [46]CHAPIRO J,DURAN R,LIN M,et al.Indentifying staging markers for hepatocellular carcinoma before transarterial chemoembolization:comparsion of three-dimensional quantitative versus nonthree-dimensional imaging markers[J].Radiology,2015,275(2):438-447.
    [47]CHAPIRO J,WOOD LD,LIN M,et al.Radiologic-pathologic analysis of contrast-enhanced and diffusion-weighted MR imaging in patients with HCC after TACE:diagnostic accuracy of 3D quantitative imaging analysis[J].Radiology,2014,273(3):746-758.
    [48]QIU GQ,XU LZ,CHEN YQ,et al.Evaluation of therapeutic effect of transcatheter arterial chemoembolization for primary hepatic carcinoma with CT perfusion imaging[J].Chin J Interv Imaging Ther,2013,10(12):717-721.(in Chinese)邱国钦,许丽贞,陈玉强,等.CT灌注成像评价经导管动脉化疗栓塞术治疗原发性肝癌的疗效[J].中国介入影像与治疗学,2013,10(12):717-721.
    [49]XU RC,LIU HC,LI JL,et al.Long-term outcome of transcatheter arterial chemoembolization after rediofrequency ablation as a combined therapy for Chinese patients with hepatocellular carcinoma[J].Curr Med Res Opin,2015,31(8):1553-1560.
  • 加载中
计量
  • 文章访问数:  2044
  • HTML全文浏览量:  28
  • PDF下载量:  553
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-10-10
  • 刊出日期:  2016-01-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回